

PATENT  
ATTORNEY DOCKET NO. 50694/017001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Crine et al.	Confirmation No.:	5955
Serial No.:	09/913,955	Art Unit:	1652
371(c) Date:	August 21, 2001	Examiner:	Delia M. Ramirez
Patent No.:	6,790,649	Customer No.:	21559
Issued:	September 14, 2004		
Title:	COMPOSITION, METHODS AND REAGENTS FOR THE SYNTHESIS OF A SOLUBLE FORM OF HUMAN PHEX		

REVOCATION AND NEW POWER OF ATTORNEY

Under 37 C.F.R. § 3.73(b), Enobia Pharma Inc., a corporation, certifies that it is the assignee of 100% of the right, title, and interest in the patent application identified above by virtue of a chain of title from the inventors of the application to the current assignee, as shown below.

1. From the inventors of the application to Université de Montréal, as recorded in the Patent and Trademark Office at Reel 012258, Frame 0956, on August 21, 2001, and at Reel 013888, Frame 0469, on March 25, 2003.
2. From Université de Montréal to Enobia Pharma Inc., as recorded in the Patent and Trademark Office at Reel 017003, Frame 0258, on November 10, 2005.

The undersigned has reviewed all the documents in the chain of title of the application and, to the best of undersigned's knowledge and belief, title is in the assignee identified above.

The undersigned, whose title is supplied below, is empowered to act on behalf of the assignee.

The undersigned, acting on behalf of the assignee, hereby revokes all powers of attorney previously granted in the application and appoints the attorneys and/or agents of Clark & Elbing LLP, associated with customer number **21559**, with full power of substitution and revocation, to prosecute the application and to transact all business in the United States Patent and Trademark Office connected therewith.

All correspondence regarding the application should be sent to the address associated with customer number **21559**.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patents issued thereon.

Respectfully submitted,

Date: October 29/2010

  
Philippe Crine, Ph.D.  
Vice President & Chief Scientific Officer  
Enobia Pharma Inc.